Background: Elevated blood glucose levels are reported with thiazide-type diuretic treatment of hypertension. The significance of this finding is uncertain. Our objectives were to compare the effect of first-step antihypertensive drug therapy with thiazide-type diuretic, calcium-channel blocker, or angiotensin-converting enzyme inhibitor on fasting glucose (FG) levels and to determine cardiovascular and renal disease risks associated with elevated FG levels and incident diabetes mellitus (DM) in 3 treatment groups.
D
IABETES MELLITUS (DM) and hypertension (HTN) share several common antecedents, including obesity and insulin resistance. 1 For this reason, treatment of one disorder may affect the other. For example, ␤-blocker or thiazide diuretic administration in nondiabetic adults may lead to raised blood glucose levels. 2, 3 Some have suggested that diuretic administration in people with DM may increase morbidity and mortality 4 ; the opposite has been observed in large randomized trials. 5 Others have suggested that administration of angiotensinconverting enzyme (ACE) inhibitors or angiotensin receptor blockers may result in lower rates of incident DM, 1,6-9 perhaps contributing to protection against cardiovascular disease (CVD). 10 Given the growing prevalence of DM, insulin resistance, and their associated CVD burden, elucidating these relationships is important.
The Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial (ALLHAT) 11 was a multicenter randomized clinical trial designed to determine whether the occurrence of fatal coronary heart disease (CHD) or nonfatal myocardial infarction is lower for high-risk patients with hypertension treated initially with a calciumchannel blocker or an ACE inhibitor compared with a diuretic. No differences were found for CHD risk. However, chlorthalidone-based treatment resulted in significantly lower heart failure risk. 11 In the present study, we conducted a post hoc analysis from the ALLHAT to investigate differences in elevated fasting glucose (FG) levels, change in FG levels, incident DM rates, and risk of CVD and renal disease by treatment assignment in participants without DM at baseline. To our knowledge, this is the largest study to examine these issues.
METHODS
Details of the ALLHAT design have been published. 12 In brief, the trial compared first-step treatment with a diuretic (chlorthalidone) with an ACE inhibitor (lisinopril) or a calciumchannel blocker (amlodipine). A fourth arm of the study, using an ␣-blocker (doxazosin) (n=9061), was stopped early 13 and is not considered in this report.
ELIGIBILITY
Eligible participants were at least 55 years old and had a systolic blood pressure of 140 mm Hg or higher, and/or a diastolic blood pressure of 90 mm Hg or higher, and/or were taking HTN medication (Ͻ3 drugs) with a blood pressure of 160/100 mm Hg or lower at randomization, and had at least 1 additional CHD risk factor. The latter included previous myocardial infarction or stroke, other manifestations of atherosclerotic CVD, left ventricular hypertrophy, a history of type 2 DM, current smoking, or low highdensity lipoprotein cholesterol level.
MEDICATIONS
Step-1 medications were formulated to look alike, so that identity of each agent was double masked. The dose of each step-1 blinded medication was titrated in an attempt to achieve a blood pressure lower than 140/90 mm Hg. If the blood pressure could not be controlled using the maximum dose of step-1 medication, open-label step-2 (reserpine, clonidine hydrochloride, or atenolol) and step-3 (hydralazinehydrochloride)medicationswereavailable.Thechoice and dose of step-2 and -3 medications were at the discretion of the investigator. Other drugs, including low doses of open-label step-1 drugclasses,werepermittedifclinicallyindicated.Potassiumsupplementation (potassium chloride) was mandated when a local recheck confirmed hypokalemia (potassium level Ͻ3.2 mEq/L).
LABORATORY TESTS
Baseline laboratory test results for glucose, lipids, creatinine, and potassium levels were obtained after an overnight fast (8 or more hours without food). Analyses were done in a certified laboratory. At years 2, 4, and 6, fasting total cholesterol and glucose levels were evaluated again. Serum potassium and creatinine levels were measured at 1 month and at years 1, 2, 4, and 6.
COHORTS FOR ANALYSIS
Baseline DM was defined by physician diagnosis (n=12 063). Evidence confirming diabetic status was not systematically sought. Those entering the trial without a DM diagnosis but with an FG level higher than 125 mg/dL (6.9 mmol/L) were defined as newly diagnosed DM cases (n=1038). Participants with newly diagnosed DM and known DM were excluded from analyses. Those with no baseline FG measurement or a baseline glucose level (nonfasting) of 110 mg/dL (6.1 mmol/L) or higher were also excluded (n=1845) (Figure 1 ).
END POINTS
The primary outcome was nonfatal myocardial infarction plus CHD death. Major prespecified secondary outcomes were (1) combined CHD (primary outcome, coronary revascularization, or hospitalized angina), (2) fatal and nonfatal stroke, (3) combined CVD (primaryoutcome,stroke,combinedCHD,othernonhospitalizedtreated angina, heart failure [fatal, hospitalized, or treated but not hospitalized], or peripheral arterial disease), and (4) all-cause mortality.Developmentofend-stagerenaldisease-requiringdialysisand/ or transplantation-was also a prespecified secondary end point.
STATISTICAL ANALYSIS
To compare baseline characteristics of participants assigned to amlodipine or lisinopril vs chlorthalidone, we used the 2 and z-tests. To analyze effects of type of HTN treatment on development of incident DM, we used logistic regression models (limited to those with Ն1 follow-up FG measurements available) over 3 periods (0-2 years, 2-4 years, and 4-6 years) adjusting for age, sex, race, FG level atthebeginningoftheinterval,bodymassindex,andcigarettesmoking. We also adjusted for the following factors (which have been observed to influence FG levels): ␤-blocker treatment, 2,14 hypokalemia, 15, 16 and statin treatment. 17 Specific first-step antihypertensive medications were entered into analyses as randomization assignment to gauge intention-to-treat effect on DM development. Kaplan-MeiercurveswereplottedandCoxregressionanalysesdone using "time to first fasting glucose level higher than 125 mg/dL (6.9 mmol/L)." These were similar to the "higher than 125 mg/dL (6.9 mmol/L) ever" results and are therefore not shown.
The effects of FG level at 2 years, change in FG level from baseline to 2 years, and incident DM at 2 years on subsequent clinical events were assessed using Cox regression models. Possible interactions of the FG level variables with treatment group were assessed. Given the many multivariate, subgroup, and interaction analyses performed, statistical significance at the .05 level should be interpreted with caution. 
RESULTS
Of 18 411 participants without diabetes at baseline, 9802 (53.2%) had 1 or more FG evaluations during follow-up. Of those without available follow-up FG values, about half had glucose values that were not fasting. Baseline characteristics of those with and without follow-up FG values were similar except for race and sex. Participants without follow-up FG values were more likely to be black or female (data not shown). Those randomized to lisinopril treatment were less likely (PϽ.001) to have follow-up FG evaluations (51.0%) than those taking chlorthalidone or amlodipine (54.0% and 54.3%, respectively). The cohort for the present study includes only those participants for whom follow-up FG values were available.
Baseline characteristics of the nondiabetic participants with follow-up FG values according to medication assignment are listed in Table 1 . There were a few small but statistically significant differences between groups with regard to the percentage of women, pulse rate, serum potassium and serum creatinine levels, and the distribution of baseline glucose levels. Abbreviations: ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); DBP, diastolic blood pressure; ECG, electrocardiography; Echo, echocardiography; FG, fasting glucose level; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LVH, left ventricular hypertrophy; SBP, systolic blood pressure.
SI conversion factors: To convert cholesterol to millimoles per liter, multiply by 0.0259; glucose to millimoles per liter, multiply by 0.0555; triglycerides to millimoles per liter, multiply by 0.0113; creatinine to micromoles per liter, multiply by 88.4.
*Unless otherwise specified, data are presented as number (percentage) of study subjects or mean (SD) value (number of subjects). †History of myocardial infarction or stroke, history of coronary revascularization, major ST segment depression or T-wave inversion on any electrocardiogram in the past 2 years, or other atherosclerotic cardiovascular disease (history of angina pectoris; history of intermittent claudication, gangrene, or ischemic ulcers; history of transient ischemic attack; coronary, peripheral vascular, or carotid stenosis Ն50% documented by angiography or Doppler studies; ischemic heart disease documented by reversible or fixed ischemia on stress thalium or dipyridamole thallium, ST depression Ն1 mm for Ն1 minute on exercise testing or Holter monitoring; reversible wall motion abnormality on stress echocardiogram; ankle-arm index Ͻ0.9; abdominal aortic aneurysm detected by ultrasonography, computed tomography, or radiography; carotid or femoral bruits).
MEDICATION ADMINISTRATION
Blinded medication administration decreased over the course of follow-up (mostly in the first year), whereas administration of open-label medications increased steadily ( Table 2 ). This was especially so for participants assigned to lisinopril (blinded medication use at year 4: lisinopril, 76.3%; amlodipine, 84.7%; chlorthalidone, 83.2%). Except for year 1, there was no difference between treatment groups with regard to atenolol administration. Those taking diuretics were more likely to be given potassium supplements, which increased from about 7% at year 1 to about 22% at year 5.
INCIDENT ELEVATED FG LEVELS
During follow-up, mean FG levels increased from baseline in all treatment groups ( and less incident DM (5.6%) (PϽ.001). From baseline to year 4, there were 1.5-mg/dL (0.08-mmol/L) and 4.0-mg/dL (0.22-mmol/L) smaller mean FG changes for those taking amlodipine (P=.07) and lisinopril (PϽ.001) than for those taking chlorthalidone. Overall, the risk of FG level ever being higher than 125 mg/dL (6.9 mmol/L) was 2.9% higher among participants taking chlorthalidone than for those taking amlodipine (PϽ.001) and 4.5% higher than for those taking lisinopril (PϽ.001). Almost all participants who developed incident DM at year 2 had FG level increases greater than 10 mg/dL (0.56 mmol/L), regardless of treatment group (Table 4) . Among those who developed DM, there was little difference in median change in FG level between those treated with chlorthalidone and amlodipine (ϩ40.0 vs ϩ38.0 Table 5) . At years 4 and 6, assignment to amlodipine or lisinopril was still associated with lower odds of developing DM, but the ORs were no longer statistically significant. Higher initial FG level, systolic blood pressure, and body mass index were associated with higher odds of developing DM from baseline to year 2 and from year 2 to year 4. Sex and age had inconsistent relationships with incident DM. Treatment with atenolol, treatment with statin medications, and hypokalemia (potassium level Ͻ3.2 mEq/dL), whether or not requiring potassium supplementation, had no significant effect on the odds of developing DM; the OR for years 4 to 6 tended to be increased for those taking supplements.
ASSOCIATION OF CHANGE IN FG LEVEL WITH CVD AND RENAL END POINTS
There was no significant effect on any of the end points in the total group and in those treated with chlorthalidone or amlodipine when the effects of a change in FG level was considered a continuous variable (Figure 2 
ASSOCIATION OF INCIDENT DM WITH OUTCOMES
The effects of incident DM (an FG level Ͼ125 mg/dL [6.9 mmol/L]) at year 2 of follow-up on study outcomes are shown in Figure 3 . In the combined treatment groups, incident DM was associated with a statistically significant increased risk of CHD (HR, 1.64 [95% CI, 1.15-2.32]). Among those taking chlorthalidone, there was no significant increase in any outcome in association with incident DM, and except for stroke, the relative risk estimates were lower than for the other 2 treatment arms. Among those taking amlodipine, incident DM was associated with increased total mortality risk (HR, 
COMMENT
In this analysis of nondiabetic older adults from the ALLHAT, FG levels increased steadily over a mean of 4.9 years, regardless of HTN treatment type. Participants randomized to treatment with chlorthalidone had a significantly higher FG level and DM incidence at years 2 and 4 of follow-up compared with those randomized to lisinopril or amlodipine treatment. These results suggest either that chlorthalidone has a detrimental effect on glucose metabolism, that lisinopril and amlodipine have a neutral or protective effect on glucose metabolism, or both.
Differences in mean FG level change between treatment groups were small (3.0 and 1.5 mg/dL [0.17 and 0.08 mmol/L] between chlorthalidone and amlodipine and 5.0 and 4.0 mg/dL [0.22 and 0.28 mmol/L] between chlorthalidone and lisinopril at years 2 and 4, respectively). These small differences translated into higher odds of DM at 2 years in those taking chlorthalidone compared with those taking amlodipine or lisinopril. Similar findings were noted in 2 other studies that reported FG level changes with different HTN medications. 18, 19 In those studies, the changes in FG levels were small (mean, 2.0-3.5 mg/dL [0.11-0.19 mmol/L]), though the relative risk of developing newonset DM was significantly increased. Unlike other studies that have examined the relationship of change in FG level with use of HTN medications, we examined the effect of such change on CVD and renal outcomes. We found that there was no effect of change in FG level on any study end point, neither for all treatment groups combined nor for the chlorthalidone group separately. Furthermore, for no outcome was the hazard ratio for a 10-mg/dL (0.56-mmol/L) change in FG level larger for chlorthalidone than for the other 2 arms. For incident DM, CHD was the only outcome with a statistically significant increased hazard ratio, and this did not differ significantly across the 3 treatment groups.
Our findings are consistent with other studies in that HRs for end points tended to be lower in those treated with chlorthalidone compared with the other groups. In the 14-year follow-up of the Systolic Hypertension in the Elderly Program, 20 DM diagnosed during chlorthalidone therapy was not associated with a significant increase in CVD mortality (HR, 1.04 [95% CI, 0.75-1.46]) Abbreviations: ACE, angiotensin-converting enzyme; BMI, body mass index; CCB, calcium-channel blocker; DBP, diastolic blood pressure; FG, fasting glucose level; K, potassium; NA, not applicable; Q, quintile cutpoint of FG; SBP, systolic blood pressure.
SI conversion factor: To convert glucose to millimoles per liter, multiply by 0.0555. *Unless otherwise indicated, data are reported as odds ratios (95% confidence intervals); diabetes mellitus is defined as FG higher than 125 mg/dL. †The quintile ranges (in milligrams per deciliter) for the 3 periods are as follows, listed 1 through 5: baseline, Ͻ84, 84-89, 90-94, 95-101, and Ͼ101; 2-year, Ͻ86, 86-91, 92-98, 99-107, and Ͼ107; 4-year, Ͻ88, 88-93, 94-100, 101-111, and Ͼ111.
‡Data on atenolol were not collected at baseline; for baseline to year 2 analysis, atenolol administration at year 1 was used. §For baseline to year 2 analysis, K value is from baseline, and K supplementation data are from the 1-year visit. For the year 2 to year 4 analysis, "KϽ3.2 mEq/dL" means that any K value up to the 2-year determination is lower than 3.2 mEq/dL; K supplementation data are from the 2-year visit. For the year 4 to year 6 analysis, "KϽ3.2 mEq/dL" means that any K value up to the 4-year determination is lower than 3.2 mEq/dL; K supplementation data are from the 4-year visit.
compared with DM that occurred in the absence of diuretic administration (HR, 1.56 [95% CI, 1.12-2.18]). In a second study, a 15-year follow-up of 686 middle-aged adults with hypertension treated with diuretics, 21 incident DM did not have a significant effect on CVD mortality, whereas prevalent DM at baseline did. An explanation for these findings comes from studies that demonstrate that cessation of long-term use of thiazide diuretics is associated with prompt improvement in glucose levels. 18 This suggests that diuretics lead to elevated glucose levels by mechanisms different from those associated with DM. Finally, our findings are consistent with a recent meta-analysis of ACE inhibitors and angiotensin receptor blockers. 19 That analysis demonstrated that while ACE inhibitors and angiotensin receptor blockers decrease DM risk, they do not reduce odds of mortality or cardiovascular or cerebrovascular events when compared with thiazides and ␤-blockers.
The finding that chlorthalidone-induced hyperglycemia and DM do not result in increased CVD outcomes is similar in certain ways to the results of the Cardiac Arrhythmia Suppression Trial. 22 In that study, a surrogate marker for the mechanism of action of the study medications-suppression of arrhythmias-did not translate into lower mortality. Indeed, the researchers found that the medications resulted in increased mortality. 22 It follows that drugs may have a positive or negative effect on a surrogate outcome (such as arrhythmia suppression or FG levels Ͼ125 mg/dL [6.9 mmol/L]) that does not necessarily translate into a positive or negative effect on risk of clinical outcomes.
Low potassium levels did not significantly increase odds of DM development in our analyses, although in the stratum given potassium supplementation (suggesting that hypokalemia was persistent enough to trigger clinical action), odds for incident DM with hypokalemia were well above unity in late follow-up. Furthermore, as the trial progressed, use of potassium supplements increased sharply (doubling at 2-5 years). Concomitantly, the differential increase in FG levels and DM incidence decreased at years 4 and 6 compared with earlier in the trial. Prior studies suggest that hypokalemia is an important intermediary factor for DM development in persons treated with diuretics, either due to diminished insulin secretion 23 or diminished insulin sensitivity. 16 A systematic review of 59 treatment trials showed a moderately high negative correlation coefficient of mean change in serum potassium and mean change in blood glucose. 24 The magnitude of the association was estimated to be about a 10-mg/dL (0.56-mmol/L) glucose level Figure 2 . Cox regression models showing the hazard ratios (95% confidence intervals) associated with a 10-mg/dL (0.56-mmol/L) increase in fasting glucose level during the first 2 years of follow-up for subsequent cardiovascular disease and renal end points in participants without diabetes mellitus at baseline. CHD indicates coronary heart disease; CCVD, combined cardiovascular disease (ie, CHD death, nonfatal myocardial infarction, coronary revascularization procedures, stroke, hospitalization or treatment for angina or heart failure, or peripheral arterial disease involving hospitalization or outpatient revascularization); ESRD, end-stage renal disease. All hazard ratios controlled for treatment group (total cohort), 2-year blood pressure, age, race, sex, smoking status, baseline fasting glucose level, baseline body mass index, 2-year serum potassium level, and atenolol and statin administration at 2 years.
increase for a 1-mEq/L decrease in potassium. An accompanying editorial concluded that the proven value of thiazides as central drugs in antihypertensive regimens may be enhanced by careful attention to prevention or management of potassium losses. 25 The present study has several strengths. Compared with other HTN trials, the ALLHAT is larger and provides much greater statistical power to recognize associations and differences between medications. Considerable attention was paid to quality assurance, and all laboratory tests were done in a certified central laboratory. Limitations should also be recognized. No FG measurements during follow-up were available for nearly half of the cohort, owing primarily to participants not fasting prior to venipuncture. Given the intrinsic variability of FG measurements, some misclassification of participants most probably occurred. This would have the effect of diluting our findings and making our estimates of incident glucose disorders conservative. We did not obtain measures of overall glucose control, such as glycosylated hemoglobin. Also, in older adults, as in this cohort, glucose abnormalities are often subtle. They are detected with the use of a 2-hour glucose challenge rather than by measurement of FG level. 26 These abnormalities were not sought in the ALLHAT. It is therefore likely that many "nondiabetic" individuals had glucose abnormalities. In community practice-based trials like the ALLHAT, investigators seek to reduce clinic and participant burden so as to maximize participation. We also did not seek information on treatment of diabetes.
Finally, our findings cannot be extrapolated beyond 5 years. Change in FG level and incident DM were evaluated at 2 years; after that, the average duration of follow-up for the analyses was about 3 years. The effects of hyperglycemia on atherosclerosis progression may occur over many decades. For example, data from the Diabetes Control and Complications Trial 27 of type 1 DM suggest that effects of elevated glucose levels on atherosclerosis, as measured by carotid intima-media thickness, occur after 10 years. Increase in glucose levels associated with such change was greater in that study, and participants had established DM (compared with our participants, who developed new-onset DM). Another report indicates that increased FG levels secondary to HTN treatment (mostly with diuretics and ␤-blockers) over more than 15 years were associated with increased CHD risk, 28 but the study failed to adjust for effects of HTN on rising glucose levels. 29 Another HTN study 30 reported a nearly 3-fold increase in CVD events with new-onset DM compared with not developing DM, but this study was based on a small number of Figure 3 . Cox regression models showing the hazard ratios (95% confidence intervals) associated with incident diabetes mellitus during the first 2 years of follow-up on subsequent cardiovascular disease and renal end points in those without diabetes mellitus at baseline. CHD indicates coronary heart disease; CCVD, combined cardiovascular disease (ie, CHD death, nonfatal myocardial infarction, coronary revascularization procedures, stroke, hospitalization or treatment for angina or heart failure, or peripheral arterial disease involving hospitalization or outpatient revascularization); ESRD, end-stage renal disease; NA, not applicable. All hazard ratios controlled for treatment group (total cohort), 2-year blood pressure, age, race, sex, smoking status, baseline fasting glucose level, baseline body mass index, 2-year serum potassium level, and atenolol and statin administration at 2 years. events (n=63) in patients who were taking combinations of medications. Whereas it found that new-onset DM was associated with increased CHD risk (similar to what we found), it did not find an independent association of diuretic administration with subsequent CHD events (again similar to our findings). A long-term follow-up study of the ALLHAT participants who developed DM while taking diuretics is planned.
In conclusion, FG levels increase in older adults with hypertension regardless of treatment with chlorthalidone, amlodipine, or lisinopril. For those taking chlorthalidone vs other treatments, the risk of developing FG levels higher than 125 mg/dL (6.9 mmol/L) is greatest, but there is no conclusive or consistent evidence that this diuretic-associated increase in DM increases the risk of clinical events.
